Asthma is a heterogeneous disease characterized by reversible airway obstruction and chronic inflammation. It has been estimated that about 300 million people suffer from chronic asthma worldwide (
1). Inflammation is the primary pathological mechanism leading to hyperresponsiveness and airway remodeling in asthma patients; it also plays a vital role in the occurrence and development of asthma (
2). In addition to chronic airway inflammation, systemic inflammatory mast cell activation occurs in patients with asthma, mediated by a variety of cell cytokines (e.g., eosinophilic neutrophils, macrophages, platelets, etc.) and a variety of mediators, which have been considered crucial in the development of clinical asthma (
3,
4).
Research on neutrophil-to-lymphocyte ratio (NLR) has gained interest over recent years. Systemic inflammation measured by NLR has a significant association with prevalent chronic conditions (
5,
6). In asthma patients, a high NLR is associated with an increased risk of severe exacerbation, and NLR has been suggested as a useful marker for asthma (
7). Research has shown that NLR and PLR may be potential diagnostic indices for pediatric recurrent wheezing (
8). However, the role of NLR in the diagnosis and assessment of bronchial asthma remains unclear.